Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Biopharma company ArsenalBio recently raised $325 million in funding, marking one of the largest biotech funding rounds of the year. This news comes as Biomarin focuses on growth plans centered around their drug for skeletal disorders. However, the gene and cell therapy investment market is currently experiencing a slowdown, with fewer funding rounds closed compared to previous years. On a positive note, a high-dose study of Biogen's spinal muscular atrophy drug showed promising results, while Denali Therapeutics and Regenxbio are moving forward with drug approval applications. In the oncology research sector, advancements in treatments, particularly in cancer immunotherapy and personalized medicine based on genetics, continue to be made. Despite these successes, there are reports of challenges faced by gene therapy companies, such as the closure of Astellas Gene Therapies' manufacturing facility affecting 100 employees and employers hesitant to cover the costs of rare disease treatments.The EU GMP Annex 1 revision has significant impacts on drug manufacturers, as non-compliance puts their ability to create and sell products in impacted markets at risk. Manufacturers must assess components for readiness to comply with the new regulations to avoid manufacturing non-compliance, potential product recalls, and market exclusions. To maintain compliance, staying informed about key considerations and taking steps to mitigate risks is crucial.Mississippi has awarded medicaid contracts to Centene, Molina, and TrueCare. Steward Health Care faced financial challenges with unprofitable deals in Massachusetts, while CEO Ralph de la Torre snubbed a Senate subpoena. Molina appointed its CFO to oversee its medicaid and ACA marketplace businesses. Healthcare providers are addressing burnout among staff, trends in telehealth and provider-payer relationships are being discussed. In California, the Senate passed a bill to regulate private-equity healthcare deals while a judge blocked Ohio from enforcing laws restricting medication abortions.Edwards recently laid off more than 500 employees after selling its critical care division to BD. The FDA has issued warning letters to four companies regarding ozone cleaners for CPAP machines. Abbott has partnered with Beta Bionics to integrate its glucose sensor with an automated insulin delivery system. The European Heart Group recommends renal denervation for some patients with uncontrolled high blood pressure.Biopharma Dive's newsletter on September 5, 2024, highlighted various key topics in the biopharma industry focusing on industry trends and developments. Additionally, it featured sponsored content on AI's role in life sciences and white papers on process analytical technology in the biopharma industry.The pharmaceutical industry faces challenges in reputation and communication with the media despite recent successes such as the development of COVID-19 vaccines. Merck & Co.'s Chief Communications and Public Affairs Officer is promoting openness and transparency in communication to improve the industry's reputation.Cell and gene therapy research is gaining interest from investors and innovators despite facing challenges in keeping up with industry growth. The latest developments focus on overcoming barriers with outside support and potential advancements in CAR-T cell therapy options.Payers can strategically use technology to build a solid data foundation by improving provider data quality through new technology tools.Researchers need to effectively collect social determinants of health (SDoH) data while ensuring privacy and security. A playbook provides insights on utilizing SDoH data effectively for health economics & outcomes research.Industry professionals are invited to join Snowflake Industry Day, a virtual event focusing on how technology leaders use